MMS19: A Protein Implicated in Cell Signaling and Neurodegenerative Diseases

Target Name: MMS19

NCBI ID: G64210

MMS19

MMS19: A Protein Implicated in Cell Signaling and Neurodegenerative Diseases

MMS19 (MMS19L) is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a member of the superfamily of transmembrane protein (SMT), which includes a group of proteins that play a critical role in cell signaling and membrane structure.

One of the unique features of MMS19 is its ability to interact with various signaling molecules, including G protein-coupled receptors (GPCRs) and ion channels. This interaction allows MMS19 to regulate a wide range of physiological processes, including cell signaling, muscle contractions, and the passage of nutrients through the intestinal tract.

MMS19 has also been shown to play a key role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these processes has led to its potential as a drug target or biomarker.

One of the primary targets for MMS19 is the GPCR, which is a family of transmembrane proteins that play a central role in cellular signaling. MMS19 has been shown to interact with several GPCRs, including the beta-adrenergic receptor (尾AR), the G protein -coupled receptor (GPCR) alpha-helix subfamily 1 (伪1) member 2 (伪1AR), and the GPCR beta-adrenergic receptor (尾AR).

These interactions allow MMS19 to modulate the activity of these GPCRs, which in turn can affect a wide range of physiological processes, including cell signaling, muscle contractions, and the passage of nutrients through the intestinal tract.

MMS19 has also been shown to play a key role in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which can lead to the debilitating symptoms associated with these conditions.

MMS19 has been shown to contribute to the development of neurofibrillary tangles and the loss of brain cells in these diseases. Its interaction with GPCRs has also been shown to play a key role in the regulation of ion channels, which are responsible for the flow of electrical current through the cell membrane. These interactions may be important for the regulation of the passage of nutrients through the intestinal tract, as well as the regulation of cell signaling.

In addition to its role in neurodegenerative diseases, MMS19 has also been shown to be involved in the development and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. These disorders are characterized by the production of antibodies that target self- antigens, including proteins such as MMS19.

MMS19's involvement in the regulation of ion channels and cell signaling has also led to its potential as a drug target. By modulating the activity of GPCRs and ion channels, MMS19 can be used to treat a wide range of disorders, including neurodegenerative diseases, neuroimmune disorders , and autoimmune disorders.

In conclusion, MMS19 is a protein that has been shown to play a critical role in a wide range of physiological processes, including cell signaling, muscle contractions, and the passage of nutrients through the intestinal tract. Its interaction with GPCRs and ion channels makes it a potential drug target or biomarker for a wide range of disorders. Further research is needed to fully understand the role of MMS19 in these processes and its potential as a therapeutic agent.

Protein Name: MMS19 Homolog, Cytosolic Iron-sulfur Assembly Component

Functions: Key component of the cytosolic iron-sulfur protein assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-sulfur cluster into apoproteins specifically involved in DNA metabolism and genomic integrity (PubMed:29848660). In the CIA complex, MMS19 acts as an adapter between early-acting CIA components and a subset of cellular target iron-sulfur proteins such as ERCC2/XPD, FANCJ and RTEL1, thereby playing a key role in nucleotide excision repair (NER), homologous recombination-mediated double-strand break DNA repair, DNA replication and RNA polymerase II (POL II) transcription (PubMed:22678362, PubMed:22678361, PubMed:29225034, PubMed:23585563). As part of the mitotic spindle-associated MMXD complex, plays a role in chromosome segregation, probably by facilitating iron-sulfur (Fe-S) cluster assembly into ERCC2/XPD (PubMed:20797633). Together with CIAO2, facilitates the transfer of Fe-S clusters to the motor protein KIF4A, which ensures proper localization of KIF4A to mitotic machinery components to promote the progression of mitosis (PubMed:29848660). Indirectly acts as a transcriptional coactivator of estrogen receptor (ER), via its role in iron-sulfur insertion into some component of the TFIIH-machinery (PubMed:11279242)

The "MMS19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMS19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets